Wednesday

Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time

TARRYTOWN, N.Y., Sept. 9 /PRNewswire/ --


Bayer Diabetes Care today introducedtwo new vibrant colors of Bayer's BREEZE(R)2 blood glucose meters -- Pink andPurple.


The BREEZE2 new color meters will offer the same unique easy to use(1)features as the original silver BREEZE2 meter, such as a 10-test disc thatstores test strips inside the meter itself, so users do not have to handleindividual strips every time they test their blood glucose. The 10-test discis a feature that nearly all BREEZE2 meter users agree makes frequent testingsimple and convenient.


Bayer Diabetes Care introduced the BREEZE2 meter colors, giving people withdiabetes the option to purchase a multi-strip meter that matches their owntaste and sense of style. The meter will also continue to be available in theoriginal silver color.


Similar to Bayer's CONTOUR(R) meter, BREEZE2 meters feature No Coding(TM)technology and no interference from maltose and galactose, making diabetesmanagement easier. In addition, the BREEZE2 meter has a small sample size, afast testing time, a large memory and holds up to 420 readings, with averagingavailable for 1-, 7-, 14- and 30-day periods.


The limited edition BREEZE2 color meters will be available at selectpharmacies while supplies last. For more information on the BREEZE2 colormeters and to download a coupon for a free BREEZE2 meter, go towww.simplewins.com/site/Adults/Monitor/Pages/Bayer-Products/Breeze-Meter.

Gastric Bypass Halts Diabetes in Obese Teens

MONDAY, Dec. 29 (HealthDay News) -- Obese teenagers who have gastric bypass surgery not only lose weight but see their type 2 diabetes disappear, a new study finds.

Also called bariatric surgery, the procedure works by limiting the size of the stomach and thereby reducing the amount of food one can eat. In this study, researchers used the Roux-en-Y method, which involves placing an adjustable band to block off most of the stomach. The band limits how much food the body absorbs.

"Previous studies have shown frequent remission of type 2 diabetes in adults following bariatric surgery, but until now, no research had been done to provide information about outcomes of adolescent diabetics who are considering surgical weight loss," said lead researcher Dr. Thomas H. Inge, an associate professor of surgery and pediatrics at Cincinnati Children's Hospital Medical Center.

"Our study found that, in most cases, teens can lose one-third of their weight and come off diabetes medications with remission of their diabetes one year after bypass surgery. This is certainly not the case for similar diabetic teenage patients who did not undergo surgery," Inge noted.

The report is published in the January issue of Pediatrics.

For the study, Inge's group looked at 78 teens with type 2 diabetes. Eleven patients underwent gastric bypass surgery, while the other 67 patients received usual care for their diabetes.

For the teens who had surgery, not only did they have an average 34 percent reduction in their weight, but their diabetes went into remission. Teens that did not have surgery saw an average weight loss of less than two pounds and still needed their diabetes medication.

"In addition to the impressive weight loss and type 2 diabetes results, patients undergoing the gastric bypass surgery also showed significant improvement in blood pressure, insulin, glucose, cholesterol and triglyceride levels," Inge said.

Type 2 diabetes takes a huge toll on the body, and the earlier it starts, the more of an impact it can have, Inge explained.

"These early surgical research findings suggest that diabetes may not be a diagnosis kids have to live with for the rest of their lives," Inge said. "They may not have to face diabetic retinopathy, progressive coronary heart disease and renal failure. In fact, there is good reason to be optimistic about their future cardiovascular health."

"If you are a type 2 diabetic and morbidly obese, gastric bypass surgery should be considered in the treatment pathway," Inge added.

Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine, thinks that while surgery is effective it does not deal with the cause of the obesity epidemic among teens.

"Bariatric surgery is clearly effective in treating severe obesity, preventing and reversing type 2 diabetes, and even extending survival when applied to adults," Katz said. "That similar benefits ensue when the procedure is applied to adolescents is important, but by no means surprising."
Despite the success of surgery, these results should be viewed with caution, Katz said.

"A large and growing proportion of all children and adolescents are subject to obesity, and its complications," Katz said. "Surgery can mitigate those complications, but can we really condone ushering more and more young people through the OR doors for a major surgical procedure to fix what policies and programs that foster healthful eating and regular activity could have prevented in the first place?"

Gastric bypass surgery is an effective last resort for severe obesity in adolescence, as in adulthood, Katz said. "But a last resort it should be, and we should do all we can to minimize the need for this procedure by combating the root causes of obesity in our society."

Friday

Class Of Diabetes Drugs Carries Significant Cardiovascular Risks

A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

"We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market," write Sonal Singh, M.D., M.P.H., assistant professor of internal medicine, and Curt D. Furberg, M.D., Ph.D., professor of public health sciences.

Rosiglitazone and pioglitazone are the two major thiazolidinediones.In the editorial Singh and Furberg say, "At this time, justification for use of thiazolidinediones is very weak to non-existent."Oral drugs are given to control diabetes by lowering blood sugar.But diabetics also experience elevated rates of high blood pressure and high levels of cholesterol and triglyceride, which "further compound their already increased risk of developing ischemic heart disease," Singh and Furberg say.

Heart disease and high blood pressure "represent conditions that are major precursors of congestive heart failure."About 22 percent of diabetics have heart disease. Among elderly patients with diabetes, more than half will develop congestive heart failure over a 10-year period, the editorial says.

The thiazolidinediones were approved for use based on the ability to reduce blood sugar.In contrast, "we reported [in the journal Diabetes Care] in June 2007 that thiazolidinediones doubled the risk of congestive heart failure in patients with type 2 diabetes," is says. "The increased heart failure appears to be a class effect."

Singh and Furberg reported in The Journal of the American Medical Association in 2007 after an analysis of four long-term trials that use of rosiglitazone was associated both with increased heart attacks and a doubling of heart failure.

They said that results from three large randomized clinical trials published this past June all failed to demonstrate that intensive control of blood sugar reduces mortality or events from cardiovascular disease in patients with type 2 diabetes.The three trials were ACCORD, ADVANCE, and the Veterans Affairs Diabetes study. In ACCORD, the patients who received intensive treatment to control blood sugar actually had more cardiovascular disease mortality than patients receiving standard treatment.

In ADVANCE, intensive control of blood sugar produced no benefit; there was no effect on cardiovascular events or deaths from cardiovascular causes compared to standard oral diabetes agents.In the VA Diabetes trial, when intensive blood sugar control produced levels of blood sugar that were too low and led to loss of consciousness, that was a strong predictor of future cardiovascular events.

"The unfavorable findings from the three trials have not been fully realized by the medical community," Singh and Furberg say.

They say that at a recent U.S. Food and Drug Administration advisory committee meeting, there was "overwhelming support for requiring reductions" of heart disease and heart failure "before approval of new oral hypoglycemic agents."

Singh said in an interview, "Safer, cheaper and more effective treatment alternatives are available that do not carry these negative cardiovascular risks in patients with diabetes. The rationale for the use of the thiazolidinediones is unclear."

Wake Forest University Baptist Medical Center (http://www.wfubmc.edu) is an academic health system comprised of North Carolina Baptist Hospital, Brenner Children's Hospital, Wake Forest University Physicians, and Wake Forest University Health Sciences, which operates the university's School of Medicine and Piedmont Triad Research Park. The system comprises 1,154 acute care, rehabilitation and long-term care beds and has been ranked as one of "America's Best Hospitals" by U.S. News & World Report since 1993. Wake Forest Baptist is ranked 32nd in the nation by America's Top Doctors for the number of its doctors considered best by their peers. The institution ranks in the top third in funding by the National Institutes of Health and fourth in the Southeast in revenues from its licensed intellectual property.